HSV G207 for Children with Recurrent Cerebellar Brain Tumors
Part of Brain & nervous system, Cancer, Infections clinical trials.
This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 21 years old.
- You have a brain tumor in the cerebellum that has come back or not responded to standard treatments.
- The tumor must be small enough (3 cm or less) for the doctors to inject the virus directly, or it can be made smaller with surgery first.
- You need to be healthy enough for brain surgery, with good blood counts and organ function.
- You cannot be taking high-dose steroids or certain antiviral/immunosuppressive drugs at the time of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether combining an HSV-tk “gene switch” treatment, valacyclovir tablets, focused radiation (SBRT), and chemotherapy can help people with recurrent glioblastoma or anaplastic astrocytoma. It may help shrink tumors or slow growth after standard treatments have already been tried.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
This trial tests whether combining G207 (a specially modified virus) with radiation therapy can help treat high-grade gliomas—aggressive brain tumors in children. G207 is designed to attack cancer cells while sparing healthy tissue.
This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.